Abstract
Objectives: The pathology of Tardive Dyskinesia (TD) has yet to be fully understood, but there have been proposed hypotheses for the cause of this condition. Our team previously reported a possible association of TD with the Complement Component C4 gene in the HLA region. In this study, we explored the HLA region further by examining two previously identified schizophrenia-associated HLA-region single-nucleotide polymorphisms (SNPs), namely rs13194504 and rs210133. Methods: The SNPs rs13194504 and rs210133 were tested for association with the occurrence and severity of TD in a sample of 172 schizophrenia patients who were recruited for four studies from three different clinical sites in Canada and USA. Results: The rs13194504 AA genotype was associated with decreased severity for TD as measured by Abnormal Involuntary Movement Scale (AIMS) scores (p = 0.047) but not for TD occurrence. SNP rs210133 was not significantly associated with either TD occurrence or AIMS scores. Conclusion: Our findings suggest that the rs13194504 AA genotype may play a role in TD severity, while SNP rs210133 may not have a major role in the risk or severity of TD.
| Original language | English (US) |
|---|---|
| Article number | e2898 |
| Journal | Human Psychopharmacology |
| Volume | 39 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 2024 |
Funding
Clement C. Zai, Arun K. Tiwari, and James L. Kennedy have patents not related to this submission. James L. Kennedy has received honoraria from Novartis, Roche, and Eli Lilly corporations, and is a member of the scientific advisory board of Myriad Neuroscience. Herbert Y. Meltzer has received grants or is or was a consultant to: Abbott Labs, ACADIA, Alkemes, Bristol Myers Squibb, DaiNippon Sumitomo, Eli Lilly, EnVivo, Janssen, Otsuka, Pfizer, Roche, Sunovion, and BiolineRx. Herbert Y. Meltzer is a shareholder of ACADIA and Glaxo Smith Kline. Jeffrey A. Lieberman receives research funding or serves on the advisory board of Allon, Alkermes, Bioline, Boehringer Ingelheim, Denovo, GlaxoSmithKline Intracellular Therapies, Lilly, Merck, Novartis, Pfizer, Pierre Fabre, Psychogenics, F. Hoffmann\u2010LaRoche Ltd., Sepracor (Sunovion), Taisho, and Targacept. Jeffrey A. Lieberman receives no direct financial compensation or salary support for participation in these research, consulting, or advisory board activities. GR has received research support from the Canadian Institutes of Health Research (CIHR), University of Toronto, and HLSTherapeutics Inc. The remaining authors declare no conflict of interest. We would like to thank Larry and Judy Tanenbaum for their generous support in creating the Tanenbaum Center for Pharmacogenetics, which is advancing research for the CAMH Pharmacogenetic Program. We would also like to thank the participants' valuable contributions to this study. Clement C. Zai and James L. Kennedy are supported by the Canadian Institutes of Health Research (PJT\u2010190232), CAMH Foundation, and Larry and Judy Tanenbaum Family Foundation. Clement C. Zai is supported by the Brain and Behavior Research Foundation.
Keywords
- genetic markers
- pharmacogenetics
- schizophrenia
- tardive dyskinesia
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
- Psychiatry and Mental health
- Pharmacology (medical)